James Crowley: Precision Cancer Therapy Advances
James Crowley, Professor of Medicine Emeritus at Brown University, Captain at U.S. Navy Reserve, shared a post on LinkedIn about a recent article by Beilei Liu et al. published in Signal Transduction and Targeted Therapy Journal:
“Emerging as the most fervently pursued research modalities are small molecule targeted agents including lipid nanoparticles, antibody-drug conjugates (ADCs), cell-based therapies, and gene therapy.
The successful application of CAR-T cell therapy by Carl June in 2011 and the FDA approval of Pembrolizumab and Nivolumab in 2014 for melanoma treatment highlighted the potential of cancer immunotherapy.
Preventive measures also evolved, as evidenced by the approval of the nine-valent Gardasil 9 vaccine, offering broader protection against HPV strains linked to cervical cancer.
In summary, much recent research has shown that gut microbiota is closely related to the occurrence and progression of tumors, as well as response to a variety of cancer therapies.
It is clear that studies on gut microbiota are essential for the prevention and treatment of cancer.
Overall, the future of precision cancer treatment will be diversified and integrated, combining traditional therapeutic methods with emerging technologies to offer patients a wider range of treatment choices.
These cutting-edge treatment modalities not only afford personalized and precise tumor targeting, but also provide patients with enhanced therapeutic comfort but the potential to impede disease progression.
The advantages, disadvantages, challenges, and representative drugs or clinical trials related to cancer treatments discussed herein are compiled in Table 7 which offers a comprehensive overview and comparison.”
Title: Exploring treatment options in cancer: tumor treatment strategies
Authors: Beilei Liu, Hongyu Zhou, Licheng Tan, Kin To Hugo Siu, Xin-Yuan Guan
Read the Full Article on Signal Transduction and Targeted Therapy Journal
Stay updated on all scientific advances with Hemostasis Today.
-
Aug 13, 2026, 18:39Lukas Röthlisberger: Real-World Evidence on Effectiveness and Safety of Rivaroxaban in Children
-
Aug 13, 2026, 18:36Soner Yilmaz: Blood Safety in Türkiye Through More Than 22.5 Million Blood Donations
-
Aug 13, 2026, 18:31Muthukumarasamy Raja: FDA Approval of EZPLAZ Marks a Breakthrough in Emergency Plasma Care
-
Aug 13, 2026, 18:29Peter Zdziarski: Protecting Our Community While Creating a Future Where We Are No Longer Needed
-
Aug 13, 2026, 18:29Morgan E Amos: Thrilled to Receive the Student Research Award From HTRS
-
Aug 13, 2026, 16:38Sheharyar Raza: Plasma Exchange in Multiple Sclerosis
-
Aug 13, 2026, 16:31Juan Manuel Cisneros Carrasco: The True Cost of Blood Donation
-
Aug 13, 2026, 16:25Connie Montgomery: Bridging the Gap Between Patients, Culture and Clinical Trials
-
Aug 13, 2026, 16:16Isabella Presch: A New AI Approach to Protein Engineering